Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Dechra Announces FDA Approval of CosACTHen® (cosyntropin injection), the First and Only Cosyntropin Approved Specifically for Canine Patients

      Dechra Corporate Logo (PRNewsfoto/Dechra)

      News provided by

      Dechra

      May 19, 2026, 08:00 ET

      Share this article

      Share this article


      This endocrine essential advances the diagnosis, confirmation and monitoring of Canine Cushing's and Addison's

      OVERLAND PARK, Kan. , May 19, 2026 /PRNewswire/ -- Dechra is proud to announce the U.S. Food and Drug Administration's (FDA) approval of CosACTHen® (cosyntropin injection), the first and only cosyntropin specifically indicated for use in canine patients. This milestone reinforces Dechra's ongoing commitment to advancing veterinary endocrinology and providing veterinarians with innovative, high-quality solutions for endocrine health.

      Continue Reading
      CosACTHen product image
      CosACTHen product image

      CosACTHen® is indicated for the evaluation of adrenal function in dogs and represents a significant advancement in the diagnosis, confirmation, and monitoring of Cushing's Disease and Addison's Disease. As an integral tool in ACTH stimulation testing, CosACTHen® provides veterinarians with confidence in assessing adrenocortical function and monitoring patients undergoing treatment with Vetoryl® Capsules (trilostane).

      "We know how challenging endocrine diagnoses can be. With CosACTHen®, veterinarians can now have the confidence of performing ACTH stimulation tests with the first and only FDA-approved cosyntropin designed specifically for canine patients," said Dr. Jill Stohs, Sr. Director Veterinary Professional Services and Medical Affairs, Dechra. "That confidence doesn't stop at the clinic, it carries through to pet parents, who can feel reassured knowing their dog's diagnosis and monitoring are supported by the latest advancement in endocrine care."

      Key Highlights of CosACTHen®:

      • Indication & Use: Indicated for the evaluation of adrenal function in dogs. Available as a 0.25 mg/ml solution in 1 ml single-use vials.

      • ACTH Stimulation Testing: CosACTHen® is integral to ACTH stimulation tests, the primary method for confirming Addison's Disease and a valuable tool for diagnosing and monitoring Cushing's Disease.

      • Dosing & Administration: Administered via intravenous or intramuscular injection, with baseline and post-stimulation cortisol levels measured to assess adrenal function.

      • Storage: Ready when needed for your urgent cases—CosACTHen® should be stored in the refrigerator.

      Reinforcing Dechra's Commitment to Veterinary Specialty Care

      With over 1,200 case consults specific to Cushing's during the last full twelve months of available data[1], CosACTHen® underscores Dechra's ongoing commitment and expertise in endocrinology.

      Supported by Dechra's Veterinary Technical Services team, veterinarians can rely on guidance, consultation and other resources to ensure best practices in endocrine diagnostics and patient care.

      "The commitment veterinary healthcare teams make to their patients drives Dechra's commitment to serving veterinarians. With CosACTHen®, clinics now have the ability to utilize the latest advancement in diagnostic and monitoring protocols for Cushing's and Addison's cases," added Dr. Stohs.

      CosACTHen® Important Safety Information

      As with all drugs, side effects may occur. For intravenous or intramuscular use in dogs only. Do not use Cosacthen in dogs that have previously had a hypersensitivity reaction to cosyntropin. The following adverse events were reported voluntarily during postapproval use of Cosacthen in dogs in foreign markets: lethargy, anxiety, muscle tremor/weakness, abdominal pain, anorexia, diarrhea, injection site pain/bruising, lameness, and hypersensitivity reactions. The safe use of Cosacthen has not been evaluated in breeding, pregnant, or lactating dogs. Not for use in humans. People with known hypersensitivity to cosyntropin or ACTH should avoid contact with the product. Pregnant and breastfeeding women should take care to avoid accidental self-injection. In case of accidental self-injection, seek medical advice immediately. If skin contact occurs, wash affected area with soap and water. Refer to the prescribing information for complete details or visit www.dechra–us.com.

      Vetoryl® Important Safety Information

      As with all drugs, side effects may occur. In field studies and post–approval experience, the most common side effects reported were: anorexia, lethargy/depression, vomiting, diarrhea, elevated liver enzymes, elevated potassium with or without decreased sodium, elevated BUN, decreased Na/K ratio, hypoadrenocorticism, weakness, elevated creatinine, shaking, and renal insufficiency. In some cases, death has been reported as an outcome of these adverse events. VETORYL Capsules are not for use in dogs with primary hepatic or renal disease, or in pregnant dogs. Refer to the prescribing information for complete details or visit www.dechra–us.com.

      About Dechra
      Dechra is a global specialist in veterinary pharmaceuticals and related products, dedicated to supporting veterinarians, pet owners, and the animals they care for. For more information, visit www.dechra-us.com.

      Media Contact
      Leslee Manley, Director, Public Relations, Dechra
      913-324-5809
      [email protected] 
      www.dechraus.com

      https://www.facebook.com/DechraUS/
      https://www.instagram.com/dechrapets_us/
      https://www.linkedin.com/company/dechra-veterinary-products/

      References

      1. Data on file. Data available July 1, 2024-June 30, 2025.

      This communication may contain information about a product that is otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for you accessing such information that may not comply with any legal process, regulation, registration or usage in the country of your origin.

      © 2026, Dechra Veterinary Products LLC., all rights reserved. Dechra is a registered trademark of Dechra Pharmaceuticals Limited. Vetoryl® and Cosacthen® are registered trademarks of Dechra Limited. C260087

      Photo - https://mma.prnewswire.com/media/2982169/CosACTHen.jpg
      Logo - https://mma.prnewswire.com/media/2919560/5975170/Dechra_Logo.jpg

      SOURCE Dechra

      Modal title

      Also from this source

      Dechra acquires biotechnology company, Gallant Pet, Inc.

      Dechra acquires biotechnology company, Gallant Pet, Inc.

      Dechra, a global leader in veterinary specialty care, today completed its acquisition of Gallant Pet Inc (Gallant), a U.S.-based animal health...

      Dechra Announces Strategic Partnership with Senior Dog Veterinary Society During National Senior Pet Month

      Dechra Announces Strategic Partnership with Senior Dog Veterinary Society During National Senior Pet Month

      Dechra, a global leader in veterinary specialty care, today announced a strategic partnership with the Senior Dog Veterinary Society (SDVS), an...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Biotechnology

      Biotechnology

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Animals & Pets

      Animals & Pets

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.